Laquinimod receives 'Fast Track'
drug status from FDA
UK study status update
For more details, please review 'Trial Status' section.
Messenger Newsletter
Click on the image below to download the latest issue of Messenger, the newsletter for MS patients in the Allegro trial.
Welcome to the ALLEGRO clinical trial website
ALLEGRO is the name given to a global clinical research trial. It is designed to explore how effective, how safe and how tolerable a new drug, called laquinimod, is in patients who have relapsing-remitting multiple sclerosis (RRMS). Laquinimod is a new investigational drug that is taken by the mouth once daily. It is hoped that laquinimod will be safe and tolerable and effective in reducing the number of relapses experienced by RRMS patients.
This website aims to give more information about ALLEGRO clinical trial. It includes general information about clinical trials and clinical trial participation, kindly provided by the UK Clinical Research Collaboration. It includes information on the rights and responsibilities of study volunteers and a list of important questions for someone to consider before joining the ALLEGRO study.
Other useful websites
